180 related articles for article (PubMed ID: 27560354)
1. A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting.
Meckel M; Kubíček V; Hermann P; Miederer M; Rösch F
Nucl Med Biol; 2016 Nov; 43(11):670-678. PubMed ID: 27560354
[TBL] [Abstract][Full Text] [Related]
2. (68)Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter.
Fellner M; Biesalski B; Bausbacher N; Kubícek V; Hermann P; Rösch F; Thews O
Nucl Med Biol; 2012 Oct; 39(7):993-9. PubMed ID: 22633217
[TBL] [Abstract][Full Text] [Related]
3. In vivo comparison of DOTA based 68Ga-labelled bisphosphonates for bone imaging in non-tumour models.
Meckel M; Fellner M; Thieme N; Bergmann R; Kubicek V; Rösch F
Nucl Med Biol; 2013 Aug; 40(6):823-30. PubMed ID: 23915801
[TBL] [Abstract][Full Text] [Related]
4. Syntheses and evaluation of
Chakraborty S; Goswami D; Chakravarty R; Mohammed SK; Sarma HD; Dash A
Chem Biol Drug Des; 2018 Sep; 92(3):1618-1626. PubMed ID: 29729071
[TBL] [Abstract][Full Text] [Related]
5. Preparation and evaluation of a radiogallium complex-conjugated bisphosphonate as a bone scintigraphy agent.
Ogawa K; Takai K; Kanbara H; Kiwada T; Kitamura Y; Shiba K; Odani A
Nucl Med Biol; 2011 Jul; 38(5):631-6. PubMed ID: 21718937
[TBL] [Abstract][Full Text] [Related]
6. New (68)Ga-PhenA bisphosphonates as potential bone imaging agents.
Wu Z; Zha Z; Choi SR; Plössl K; Zhu L; Kung HF
Nucl Med Biol; 2016 Jun; 43(6):360-71. PubMed ID: 27260777
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of a novel 68Ga-chelate-conjugated bisphosphonate as a bone-seeking agent for PET imaging.
Suzuki K; Satake M; Suwada J; Oshikiri S; Ashino H; Dozono H; Hino A; Kasahara H; Minamizawa T
Nucl Med Biol; 2011 Oct; 38(7):1011-8. PubMed ID: 21982572
[TBL] [Abstract][Full Text] [Related]
8. A bisphosphonate monoamide analogue of DOTA: a potential agent for bone targeting.
Kubícek V; Rudovský J; Kotek J; Hermann P; Vander Elst L; Muller RN; Kolar ZI; Wolterbeek HT; Peters JA; Lukes I
J Am Chem Soc; 2005 Nov; 127(47):16477-85. PubMed ID: 16305234
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, Quality Control, and Bench-to-Bed Translation of a New [
Chakraborty S; Chatterjee S; Chakravarty R; Sarma HD; Nanabala R; Goswami D; Joy A; Pillai MRA
Cancer Biother Radiopharm; 2024 Feb; 39(1):92-101. PubMed ID: 38335449
[No Abstract] [Full Text] [Related]
10. Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid.
Meckel M; Bergmann R; Miederer M; Roesch F
EJNMMI Radiopharm Chem; 2017; 1(1):14. PubMed ID: 29564390
[TBL] [Abstract][Full Text] [Related]
11. Preliminary results of biodistribution and dosimetric analysis of [
Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Ann Nucl Med; 2019 Jun; 33(6):404-413. PubMed ID: 30877560
[TBL] [Abstract][Full Text] [Related]
12. [
Keeling GP; Sherin B; Kim J; San Juan B; Grus T; Eykyn TR; Rösch F; Smith GE; Blower PJ; Terry SYA; T M de Rosales R
Bioconjug Chem; 2021 Jul; 32(7):1276-1289. PubMed ID: 32786371
[TBL] [Abstract][Full Text] [Related]
13. Development of novel radiogallium-labeled bone imaging agents using oligo-aspartic acid peptides as carriers.
Ogawa K; Ishizaki A; Takai K; Kitamura Y; Kiwada T; Shiba K; Odani A
PLoS One; 2013; 8(12):e84335. PubMed ID: 24391942
[TBL] [Abstract][Full Text] [Related]
14. Preparation, Characterization, and Radiolabeling of [
Ashhar Z; Yusof NA; Ahmad Saad FF; Mohd Nor SM; Mohammad F; Bahrin Wan Kamal WH; Hassan MH; Ahmad Hassali H; Al-Lohedan HA
Molecules; 2020 Jun; 25(11):. PubMed ID: 32526838
[TBL] [Abstract][Full Text] [Related]
15. Convenient Formulation of
Guleria M; Das T; Amirdhanayagam J; Shinto AS; Kamaleshwaran KK; Pandian A; Sarma HD; Dash A
Cancer Biother Radiopharm; 2019 Mar; 34(2):67-75. PubMed ID: 30394799
[TBL] [Abstract][Full Text] [Related]
16. Theranostic Agent Targeting Bone Metastasis: A Novel [
Jin W; Zhao R; Wang R; Choi SR; Ploessl K; Alexoff D; Wu Z; Zhu L; Kung HF
J Med Chem; 2024 Mar; 67(6):4793-4803. PubMed ID: 38450559
[TBL] [Abstract][Full Text] [Related]
17. Complexes of DOTA-bisphosphonate conjugates: probes for determination of adsorption capacity and affinity constants of hydroxyapatite.
Vitha T; Kubícek V; Hermann P; Kolar ZI; Wolterbeek HT; Peters JA; Lukes I
Langmuir; 2008 Mar; 24(5):1952-8. PubMed ID: 18225929
[TBL] [Abstract][Full Text] [Related]
18. Preparation, quality control and biodistribution assessment of ¹⁵³Sm-BPAMD as a novel agent for bone pain palliation therapy.
Rabie A; Enayati R; Yousefnia H; Jalilian AR; Shamsaei M; Zolghadri S; Bahrami-Samani A; Hosntalab M
Ann Nucl Med; 2015 Dec; 29(10):870-6. PubMed ID: 26260999
[TBL] [Abstract][Full Text] [Related]
19. Development of [(90)Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases.
Ogawa K; Kawashima H; Shiba K; Washiyama K; Yoshimoto M; Kiyono Y; Ueda M; Mori H; Saji H
Nucl Med Biol; 2009 Feb; 36(2):129-35. PubMed ID: 19217524
[TBL] [Abstract][Full Text] [Related]
20. Gallium(III) complexes of NOTA-bis (phosphonate) conjugates as PET radiotracers for bone imaging.
Holub J; Meckel M; Kubíček V; Rösch F; Hermann P
Contrast Media Mol Imaging; 2015; 10(2):122-34. PubMed ID: 24801892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
